Phase I Clinical Study of ABI-007 in Combination with Gemcitabine as Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 03 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2016 Status changed from not yet recruiting to recruiting.
- 10 Jun 2016 New trial record